Pitt, M <br/><br/>
Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.  [electronic resource] 

 -  Health technology assessment (Winchester, England)  Oct 2010 
 - 41-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>2046-4924 
<br/><br/><label>Standard No.: </label>10.3310/hta14suppl2/06  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--economics<br/>Carcinoma, Renal Cell--drug therapy<br/>Cost-Benefit Analysis<br/>England<br/>Everolimus<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Randomized Controlled Trials as Topic<br/>Sirolimus--analogs & derivatives<br/>Wales